手术切除联合咪喹莫特乳膏治疗尖锐湿疣的疗效观察

目的观察手术切除较大疣体后继用5%咪喹莫特乳膏治疗8周减少尖锐湿疣复发的疗效和安全性。方法58例尖锐湿疣患者中32例仅进行手术切除疣体(手术治疗组),另外26例在手术切除疣体创面愈合后外用5%咪喹莫特乳膏8周(联合治疗组)。观察患者在4,8,12周时的复发率及不良反应。结果手术治疗组在4周,8周和12周时的复发率分别为25.0%,13.0%和16.0%,联合治疗组的复发率分别为8.3%,0和0。5%咪喹莫特乳膏的局部不良反应发生率为80.1%,主要表现为用药局部红斑、瘙痒、水肿、灼热、疼痛和糜烂,但均能耐受且暂停用药后可迅速消退,无系统不良反应发生。结论手术切除后继用5%咪喹莫特乳膏8周,可能是一种安全且可降低尖锐湿疣复发率的治疗方法。     

不同疗程5％咪喹莫特乳膏预防尖锐湿疣的复发

目的 探讨应用不同疗程5％咪喹莫特乳膏预防尖锐湿疣复发的疗效和安全性。方法 采用随机、对照的方法，将患者分成3组：A组单用CO2激光治疗；B组用CO2激光祛除疣体后外用5％咪喹莫特乳膏4周，每周3次；C组用CO2激光祛除疣体后外用5％咪喹莫特乳膏8周，每周3次。所有患者均随访6个月。结果 共有90例外生殖器及肛周尖锐湿疣患者完成临床研究．6个月后．3组的复发率分别为64．29％、50％及21．88％，3组复发率比较，差异有统计学意义（P=0．0033）。外用咪喹莫特乳膏8周组复发率低于前两组；外用4周组与8周组复发率比较，差异有统计学意义（P=0．0207）。激光治疗后外用5％咪喹莫特乳膏4周组与8周组出现的不良反应率分别为73．33％．84．38％。不良反应包括：红斑、瘙痒、疼痛、灼热、糜烂、溃疡，以及流感样症状，两组差异无统计学意义（P〉0．05）。结论 激光治疗后外用5％咪喹莫特乳膏8周．皮损的复发率比外用4周明显下降。两组安全性无明显差异。     

咪喹莫特乳膏预防尖锐湿疣复发的疗效观察

目的 探讨CO2激光术后外用咪喹莫特乳膏预防尖锐湿疣（CA）复发的情况。方法 治疗组采用CO2激光术后联合外用咪喹莫特乳膏治疗8周，对照组单用CO2激光治疗。随访6个月，对两组的复发情况进行比较。结果 治疗组复发率低于对照组，两组复发率比较差异有显著性（P〈0．05）。结论 眯喹莫特乳膏外用可以降低CA的复发率。     

CO2激光联合咪喹莫特乳膏预防尖锐湿疣复发疗效观察

目的探讨C02激光联合咪喹莫特乳膏预防尖锐湿疣（CA）复发的疗效。方法将74例患者随机分成两组，治疗组在CO2激光术后局部外用咪喹莫特8周，对照组单用CO2激光治疗，两组均随访3个月，观察患者复发情况。结果治疗组复发率为12．5％，对照组为38．2％，两组比较差异有统计学意义（P〈0．05）。结论CO2激光联合咪喹莫特乳膏治疗尖锐湿疣能明显降低其复发率。     

5％咪喹莫特乳膏对激光术后女性尖锐湿疣患者的影响

目的：探讨CO,激光术后局部外用涂抹5％咪喹莫特乳膏对女性尖锐湿疣复发的影响。方法：选择2010年3月～2012年1月在我院进行CO,激光术后的女性尖锐湿疣患者为研究对象,随机分成甲组、乙组和丙组,其中甲组91例,采用5％咪喹莫特乳膏涂抹病灶区,隔天一次;乙组82例,采用重组人干扰素d-2b凝胶,每天使用4次,甲乙两组疗程均为4周;丙组86例,单用CO,激光治疗,治疗后三组均随访12周。结果：经过治疗后甲组、乙组、丙组治愈率分别是92．32％、76．83％、63．94％,复发率分别是7．68％、23．17％、36．06％,甲组治愈率明显高于乙组和丙组,复发率明显低于乙组和丙组,甲组与乙组和丙组治愈率相比差异有统计学意义（P〈0．05）,乙组和丙组治愈率相比差异无统计学意义（P〉0．05）,甲乙两组均有轻度的不良反应,对治疗无不良影响。结论：女性尖锐湿疣患者在施行CO2激光术后给予局部皮损处及其周围涂抹5％咪喹莫特乳膏,可有效的降低尖锐湿疣的复发率,且不良反应少,并可耐受。     

CO2激光联合5-Fu外用治疗尖锐湿疣的临床观察

目的：评价CO2激光治疗后继外用5-Fu预防尖锐湿疣（CA）复发的临床疗效。方法：将183例用CO2激光治疗的尖锐湿疣患者设为激光治疗组,将195例CO2激光创面愈合后再外用5-Fu 10周尖锐湿疣患者设为联合治疗组：所有患者均有详细的治疗方案和随诊记录,对患者在4周、8周、12周的复发情况及不良反应进行记录。结果：激光治疗组在4周、8周、12周时的复发率分别为33．3％、18．6％、9．8％,而联合治疗组相应的复发率为13．6％、3．6％、1．0％。5-Fu的局部不良反应发生率为5．6％,主要表现为红肿灼热3．2％,糜烂渗出2．4％,其局部不良反应可耐受且暂停用药并适当处理可迅速痊愈,无系统不良反应。结论：CO2激光治疗尖锐湿疣后继外用5-Fu能有效、安全地预防CA复发。     

CO2激光治疗联合咪喹莫特乳膏治疗女性尖锐湿疣的临床疗效观察

目的：探讨CO2激光治疗联合5％咪喹莫特乳膏在女性尖锐湿疣治疗中的临床应用价值.方法：选取我院收治的80例女性尖锐湿疣患者,随机分为两组,均签署知情同意书.对照组采用CO2激光治疗联合阿昔洛韦软膏外用的治疗方法;治疗组采用CO2激光治疗联合5％咪喹莫特乳膏外用的治疗方法,治疗期为1个月,观察3个月后两组患者的治愈率、复发率以及其安全性.结果：治疗组总有效率为97.5％,对照组总有效率率为87.5％,治疗组总有效率明显高于对照组（P＜0.05）;治疗组复发率为12.5％,对照组复发率为30.0％,治疗组复发率明显低于对照组（P＜0.05）.治疗期间观察各组均无明显副作用.结论：女性尖锐湿疣经CO2激光治疗后外用5％咪喹英特乳膏的临床效果优于外用阿昔洛韦软膏,且未发现明显不良反应,值得临床推广及应用.     

激光治疗尖锐湿疣后外用咪喹莫特乳膏的效果研究

目的:探讨激光治疗尖锐湿疣后外用咪喹莫特乳膏治疗的效果。方法:选择我院2013年3月至2015年3月治疗的尖锐湿疣患者110例,按照治疗方案分为激光组(50例)和联合治疗组(60例),比较两组患者在治疗后的痊愈率和第4、8、12周的复发率和治疗后不良反应。结果:联合治疗组治疗后的痊愈率明显高于激光组,而同期的复发率明显低于激光组,两组上述数据比较,差异有统计学意义(P0.05);而两组患者的并发症发生率比较,差异未见统计学意义(P0.05)。12周后联合治疗组的CD3+、CD4~+T淋巴细胞百分率及CD4~+/CD8~+值明显高于激光组,而CD8~+T淋巴细胞百分数明显低于激光组,差异有统计学意义(P0.05)。结论:激光治疗尖锐湿疣后继用5%咪喹莫特乳膏是一种安全有效的治疗方案。     

5%咪喹莫特乳膏外用治疗尖锐湿疣70例

目的观察5％咪喹莫特乳膏外用治疗外生殖器尖锐湿疣的临床疗效。方法治疗组采用5％咪喹莫特乳膏外擦尖锐湿疣，隔日一次，共三个月；对照组采用0．5％足叶草毒素酊外擦尖锐湿疣，早晚一次，共3d为一个疗程，最多不超过三个疗程。结果治疗组70例患者，治疗组治愈51例（72．86％），无效19例（27．14％）；对照组70例患者，治愈36例（51．43％），无效34例（48．57％）。两组治愈率比较差异有统计学意义（X^2=6．83，P〈0．01）。结论5％咪喹莫特乳膏外用治疗外生殖器尖锐湿疣疗效好，安全性高，是一种较理想的治疗方法。     

5％眯喹莫特乳膏外用治疗尖锐湿疣70例

目的观察5％咪喹莫特乳膏外用治疗外生殖器尖锐湿疣的临床疗效。方法治疗组采用5％咪喹莫特乳膏外擦尖锐湿疣，隔日一次，共三个月；对照组采用0．5％足叶草毒素酊外擦尖锐湿疣，早晚一次，共3d为一个疗程，最多不超过三个疗程。结果治疗组70例患者，治疗组治愈51例（72．86％），无效19例（27．14％）；对照组70例患者，治愈36例（51．43％），无效34例（48．57％）。两组治愈率比较差异有统计学意义（X^2=6．83，P〈0．01）。结论5％咪喹莫特乳膏外用治疗外生殖器尖锐湿疣疗效好，安全性高，是一种较理想的治疗方法。     

5%咪喹莫特乳膏外用预防尖锐湿疣复发的疗效观察

目的观察5%咪喹莫特乳膏外用预防尖锐湿疣(CA)复发的疗效。方法治疗组43例CA患者予二氧化碳激光祛除疣体后1周于原皮疹部位及其周围0.5cm范围外用5%咪喹莫特乳膏,隔日1次,疗程1月,对照组38例CA患者单用二氧化碳激光治疗,治疗后两组均随访3个月。结果治疗组复发率(6.97%,3/43)明显低于对照组(42.10%,16/38)(P<0.01)。结论 5%咪喹莫特乳膏外用可以明显降低CA的复发率。     

香菇菌多糖联合5%咪喹莫特乳膏预防尖锐湿疣CO_2激光术后复发的疗效观察

目的观察CO2激光去除疣体后,联合应用全身及局部免疫调节剂香菇菌多糖和5%咪喹莫特乳膏预防尖锐湿疣复发的疗效。方法将患者按就诊先后随机分为三组,先用CO2激光去除疣体后:A组给予口服香菇菌多糖片10mg,3次/d;待创面愈合后,同时给予5%咪喹莫特乳膏外用,每周二、四、六晚涂药3次。B组单纯给予5%咪喹莫特乳膏外用。C组单纯给予口服香菇菌多糖片。用法及用量同A组。3组疗程均为8周。观察复发情况及不良反应,12周后进行复发率比较。结果 2周后A,B,C3组的复发率分别为10.42%,30.00%,33.33%。A组复发率明显低于B,C组,差异有统计学意义(P均<0.05)。结论联合应用免疫调节剂香菇菌多糖和5%咪喹莫特乳膏预防尖锐湿疣复发疗效好,复发率低。     

Successful treatment of actinic keratosis with imiquimod cream 5%: a report of six cases

BACKGROUND: Actinic keratoses (AK) are premalignant lesions, which are routinely treated by destructive procedures such as cryotherapy, electrodessication or topical 5-fluorouracil. OBJECTIVES: The aim of this study is to report six cases of AK treated with a potential new topical therapy, imiquimod. METHODS: Subjects included in this study had suffered with recurrent AK for between 5 and 16 years. All six men were treated with imiquimod 5% cream three times a week for 6-8 weeks. In the event of a local skin reaction treatment was modified to two times per week. RESULTS: All the AK lesions were successfully cleared after treatment with imiquimod cream 5% for 6-8 weeks. Histologically, no apparent signs of persisting AK could be detected, and no recurrences were reported during follow up. CONCLUSIONS: This study suggests that imiquimod may be useful as a new therapy for the treatment of actinic keratoses.     

得宝松局封联合咪喹莫特乳膏治疗瘢痕疙瘩疗效评价

目的:评价复方倍他米松注射液皮损内注射联合5%咪喹莫特乳膏外涂治疗瘢痕疙瘩的疗效。方法:将患者随机分为两组,治疗组给予复方倍他米松注射液皮损内注射,每3周1次,共3次。同时给予隔日外涂5%咪喹莫特乳膏,连续3个月;对照组单纯给予复方倍他米松注射液皮损内注射。两组患者均于疗程结束后6个月评价疗效和复发。结果:治疗组有效率93.55%,对照组有效率70.37%,复发率治疗组低于对照组,差异有显著性意义,不良反应轻微。结论:复方倍他米松注射液皮损内注射联合5%咪喹莫特乳膏外涂治疗瘢痕疙瘩安全、有效。     

Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind,randomized, vehicle-controlled study

BACKGROUND: Imiquimod 5% cream may provide an effective nonsurgical treatment for superficial basal cell carcinoma (sBCC) based on results of previous studies. OBJECTIVE: The objective of this phase II dose-response study was to explore various dosing regimens using imiquimod 5% cream for sBCC to find the most effective frequency of dosing with tolerable side effects. METHODS: Patients (n = 128) were dosed twice daily, once daily, 5 times a week, or 3 times a week in this 12-week, randomized, double-blind, vehicle-controlled study. At 6 weeks after treatment, the entire tumor area was clinically evaluated, excised, and examined exhaustively for histologic evidence of residual sBCC. RESULTS: Complete response rates were 100% (10/10), 87.1% (27/31), 80.8% (21/26), and 51.7% (15/29) for patients in the twice daily, once daily, 5 times a week, and 3 times a week imiquimod groups, respectively, and 18.8% (6/32) in the vehicle group. CONCLUSION: Imiquimod 5% cream was effective in the treatment of sBCC. Daily or 5 times a week dosing for 12 weeks demonstrated high efficacy results with acceptable safety profiles.     

Clinical effect of imiquimod 5% cream in the treatment of actinic keratosis

BACKGROUND: Actinic keratosis (AK) is the earliest clinical manifestation of squamous cell carcinoma. Metastatic SCC causes the majority of the 1300 to 2300 deaths attributed to nonmelanoma skin cancer in the United States each year. Recent studies have shown that intralesional administration of interferon can be used successfully in the treatment of AK. OBJECTIVE: Imiquimod is an immune response modifier, currently approved for the treatment of genital warts. The topically applied immune response modifier acts by up-regulating interferon and other cytokines involved in the cell-mediated immune response at the site of application. The aim of this was to determine the efficacy and safety of imiquimod 5% cream for the treatment of AK. METHODS: Twenty-two patients with AK lesions were treated with imiquimod 5% cream, initially at 3 times per week for 8 weeks, or until total clearance of lesions. Patients applied imiquimod to lesions on one side of the body and vehicle cream to the other side. A total of 17 patients who completed treatment were evaluated for number of lesions and adverse reactions before treatment and at weeks 2, 4, 6, and 8 after initiation of treatment. AK lesions were also assessed 4 and 8 weeks after treatment. RESULTS: A significant reduction in the average number of lesions per patient was observed for patients treated with imiquimod. The most frequent reactions to treatment were erythema, itching, and scabbing; however, all adverse events were mild to moderate. CONCLUSION: Imiquimod 5% cream may be a promising treatment for AK.     

Vagarious successful treatment of recalcitrant warts in combination with CO2 laser and imiquimod 5% cream

Abstract

Background. Imiquimod 5% cream is widely regarded as a safe and effective option when treating recalcitrant warts, owing to the ointment's negligible side effects. However, our observations highlighted case of a patient incurring severe adverse reactions due to application of the cream, although the treatment proved successful in curing recalcitrant warts which had developed on the external auditory canal and external ear. Methods. All lesions were entirely removed with short-pulsed CO₂ laser. As soon as the wound-healing process was completed, imiquimod 5% cream was self-applied on the healing wounds once daily for 5 days per week in a total of 2 weeks. Results. The patient appeared normal after the CO₂ laser treatment and experienced severe redness, itching, exudation, and incrustation after a 2-week imiquimod 5% cream therapy. All lesions showed no recurrence during the 12-month followed-up process. Conclusions. We concluded that a feasible treatment modality to cure recalcitrant cutaneous warts is in combination of CO₂ laser and imiquimod. Immunoenhancement plays an important role in the treatment of recalcitrant warts.     

5%咪喹莫特乳膏治疗尖锐湿疣的多中心、随机双盲、对照研究

目的评价5%咪喹莫特乳膏治疗尖锐湿疣的疗效和安全性,并与2.5%5-氟脲嘧啶乳膏进行对照。方法对尖锐湿疣患者进行多中心、随机双盲、平行对照的临床试验研究。5%咪喹莫特乳膏试验组和2.5%5-氟脲嘧啶乳膏对照组均每周外用药物3次,共治疗8周。结果本研究共244例患者完成全部观察,其中,咪喹莫特组125例,5-氟脲嘧啶组119例。咪喹莫特组治疗后2、4、6、8周的痊愈率分别为52.00%、74.40%、81.60%、92.80%、有效率分别为79.20%、93.60%、97.60%、97.60%.5-氟脲嘧啶组治疗后2、4、6、8周的痊愈率分别为52.10%、70.59%,78.15%、89.92%、有效率分别为84.03%、94.12%、94.96%、97.48%。两组差异均无统计学意义(P>0.05)。不良事件主要为局部不良反应,如局部红斑、疼痛、糜烂,瘙痒等,未见系统性不良反应。结论5%咪喹莫特乳膏治疗尖锐湿疣疗效确切,使用方法简便,耐受性较好。     

A randomized,double-blind,vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses

BACKGROUND: Actinic keratoses (AKs) are precancerous epidermal lesions found most frequently on areas of the skin exposed to the sun. Several case studies published recently have indicated that 5% imiquimod cream, currently licensed for the treatment of genital warts, may be an effective treatment for AK. OBJECTIVE: To assess the efficacy and safety of imiquimod for the treatment of AK. DESIGN: Patients in this randomized, double-blind, vehicle-controlled study applied 5% imiquimod cream or vehicle to AK lesions 3 times per week for a maximum of 12 weeks or until lesions had resolved. In the event of an adverse reaction, application of imiquimod was reduced to 1 or 2 times per week. Rest periods were also allowed if necessary. SETTING: A specialized outpatient dermatology clinic within a state-funded hospital in Germany. PATIENTS: The study population was aged 45 to 85 years. Of 52 patients screened, 36 men and women with AK confirmed by histological diagnosis were enrolled. Patients were excluded from the study if they did not have a histological diagnosis for AK, if they were older than 85 years, or if they did not comply with the protocol. All patients had responded to a notice asking for volunteers. MAIN OUTCOME MEASURES: The number and appearance of lesions were evaluated before, during, and after treatment. All adverse effects were recorded. RESULTS: Lesions treated with 5% imiquimod cream were clinically cleared in 21 (84%) of 25 patients and partially cleared in 2 (8%). Clearance was histologically confirmed 2 weeks after the last application of imiquimod in all patients clinically diagnosed as lesion free. Only 10% of patients treated with imiquimod were clinically diagnosed with recurrence 1 year after treatment. No reduction in the size or number of AK lesions was observed in vehicle-treated patients. Adverse effects reported by patients treated with imiquimod included erythema, edema, induration, vesicles, erosion, ulceration, excoriation, and scabbing. However, imiquimod was well tolerated since all patients completed the 12-week treatment. Only a few, mild adverse reactions to the vehicle cream were reported. CONCLUSION: Application of 5% imiquimod cream for 12 weeks is an effective and well-tolerated treatment for AK.     

5%咪喹莫特乳膏对CO_2激光术后女性尖锐湿疣复发的预防作用

目的了解CO2激光术后局部外用5%咪喹莫特乳膏对女性生殖器尖锐湿疣(CA)复发的预防作用。方法 64例女性生殖器尖锐湿疣患者予CO2激光去除肉眼可见的疣体后随机分为A,B两组,每组32例,A组外用5%咪喹莫特乳膏,每周一、三、五或二、四、六晚各1次;B组外用重组人干扰素α-2b凝胶,4次/d。两组疗程均为8周,随访3个月,比较两组患者治愈、复发和不良反应情况。结果 A,B两组的治愈率分别为93.75%和71.88%,复发率为6.25%和28.12%,差异均有统计学意义(P均0.05);A,B两组不良反应发生率分别为65.60%和25.00%,差异也有统计学意义(P0.01)。结论 CO2激光去除疣体后局部外用5%咪喹莫特乳膏比重组人干扰素α-2b凝胶能更有效阻止女性生殖器尖锐湿疣的复发。